Strides Pharma Science Limited (BOM:532531)
813.55
+0.05 (0.01%)
At close: Oct 28, 2025
Strides Pharma Science Employees
Strides Pharma Science had 3,301 employees as of March 31, 2025. The number of employees increased by 236 or 7.70% compared to the previous year.
Employees
3,301
Change (1Y)
236
Growth (1Y)
7.70%
Revenue / Employee
14.18M INR
Profits / Employee
1.20M INR
Market Cap
86.15B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 3,301 | 236 | 7.70% |
| Mar 31, 2024 | 3,065 | 215 | 7.54% |
| Mar 31, 2023 | 2,850 | 203 | 7.67% |
| Mar 31, 2022 | 2,647 | 257 | 10.75% |
| Mar 31, 2021 | 2,390 | -579 | -19.50% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tata Consultancy Services | 607,979 |
| Reliance Industries | 403,303 |
| Infosys | 323,578 |
| State Bank of India | 236,226 |
| HDFC Bank | 214,521 |
| ICICI Bank | 182,665 |
| Life Insurance Corporation of India | 91,606 |
| Bajaj Finance | 64,092 |
Strides Pharma Science News
- 3 months ago - Strides Pharma shares hit 52-week high, jumps 3% after Q1 PAT jumps 81% YoY - Business Upturn
- 3 months ago - Strides Pharma Q1 Results: Revenue rises 6.2% YoY to Rs 1119 crore, Net Profit at Rs 105.6 crore - Business Upturn
- 6 months ago - Strides Pharma receives USFDA approval for Celecoxib Capsules - Business Upturn
- 7 months ago - Strides Pharma incorporates new subsidiary ‘Pivot Path’ to boost life sciences and digital innovation - Business Upturn
- 9 months ago - Strides Pharma shares surge 5% as revenue jumps 15% YoY in Q3 FY25 - Business Upturn
- 9 months ago - Strides Pharma Q3 FY25 Results: Revenue up 15% YoY to Rs 1,154 crore, Net Profit up 60% YoY - Business Upturn
- 10 months ago - Strides Pharma receives USFDA approval for acetaminophen and ibuprofen tablets, expanding OTC portfolio - Business Upturn